Then we investigated the treatment effects of LMHFV therapy on the maintenance of the NMJ during the onset of sarcopenia in SAMP8 with respect to the Agrin‐LRP4‐MuSK‐Dok7‐Rapsyn pathway and extracellular signal‐regulated kinase (ERK)1/2 signaling. The gene discussed is LRP4; the disease is sarcopenia.